NatureWise Biotech & Medicals Corporation (TPEX:4732)
15.50
0.00 (0.00%)
Oct 30, 2026, 10:09 AM CST
TPEX:4732 Revenue
NatureWise Biotech & Medicals had revenue of 84.62M TWD in the half year ending June 30, 2026, a decrease of -35.30%. This brings the company's total for the last twelve months to 174.62M, down -3.15% year-over-year. In the year 2025, NatureWise Biotech & Medicals had annual revenue of 176.77M, down -21.20%. That makes NatureWise Biotech & Medicals the 39,730th largest company in the world by revenue and 2,054th in Taiwan.
Revenue (ttm)
174.62M
Revenue Growth
-3.15%
P/S Ratio
4.30
Revenue / Employee
5.46M
Employees
31
Market Cap
751.08M
Revenue by Geography
- Taiwan 172.10M 97.4%
- Mainland China 4.50M 2.5%
- Other 166.00K 0.1%
Fiscal year ended Dec 31, 2025 See the full TPEX:4732 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 176.77M | -47.56M | -21.20% |
| Dec 31, 2024 | 224.32M | 64.18M | 40.08% |
| Dec 31, 2023 | 160.14M | -68.45M | -29.94% |
| Dec 31, 2022 | 228.59M | -21.21M | -8.49% |
| Dec 31, 2021 | 249.80M | -57.12M | -18.61% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Meribank Biotech | 408.48M |
| Taiwan Advance Bio-Pharmaceutical | 348.54M |
| BioLASCO Taiwan | 258.04M |
| TCI GENE | 251.39M |
| GeneReach Biotechnology | 238.08M |
| Lukas Biomedical | 170.01M |
| Enimmune | 53.45M |
| Holy Stone Healthcare | 47.51M |